{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:30:29Z","timestamp":1792456229506,"version":"4.5.0"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The fallopian tube is now generally considered the dominant site of origin for high-grade serous ovarian carcinoma. However, the molecular pathogenesis of fallopian tube-derived serous carcinomas is poorly understood and there are few experimental studies examining the transformation of human fallopian tube cells. Prompted by recent genomic analyses that identified cyclin E1 (CCNE1) gene amplification as a candidate oncogenic driver in high-grade serous ovarian carcinoma, we evaluated the functional role of cyclin E1 in serous carcinogenesis. Cyclin E1 was expressed in early- and late-stage human tumor samples. In primary human fallopian tube secretory epithelial cells, cyclin E1 expression imparted malignant characteristics to untransformed cells if p53 was compromised, promoting an accumulation of DNA damage and altered transcription of DNA damage response genes related to DNA replication stress. Together, our findings corroborate the hypothesis that cyclin E1 dysregulation acts to drive malignant transformation in fallopian tube secretory cells that are the site of origin of high-grade serous ovarian carcinomas. Cancer Res; 74(4); 1141\u201352. \u00a92013 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-13-2247","type":"journal-article","created":{"date-parts":[[2013,12,23]],"date-time":"2013-12-23T23:21:25Z","timestamp":1387840885000},"page":"1141-1152","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":196,"title":["Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube\u2013Derived High-Grade Serous Ovarian Cancers"],"prefix":"10.1158","volume":"74","author":[{"given":"Alison M.","family":"Karst","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Vena","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra H.","family":"Ligon","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariush","family":"Etemadmoghadam","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.L.","family":"Bowtell","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Drapkin","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Authors' Affiliations:\u20081Department of Medical Oncology; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Department of Pathology, Division of Cytogenetics; 5Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 6Peter MacCallum Cancer Centre, East Melbourne; 7Department of Oncology, Peter MacCallum Cancer Centre; Departments of 8Pathology and 9Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2014,2,16]]},"reference":[{"key":"2022061704592231200_bib1","article-title":"World cancer report 2008","author":"Boyle","year":"2008"},{"key":"2022061704592231200_bib2","first-page":"27","article-title":"Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma","volume":"16","author":"Nik","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"2022061704592231200_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J Pathol"},{"key":"2022061704592231200_bib4","doi-asserted-by":"crossref","first-page":"viii28","DOI":"10.1093\/annonc\/mdt308","article-title":"Coming into focus: the nonovarian origins of ovarian cancer","volume":"24","author":"Dubeau","year":"2013","journal-title":"Ann Oncol"},{"key":"2022061704592231200_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"TCGA","year":"2011","journal-title":"Nature"},{"key":"2022061704592231200_bib6","doi-asserted-by":"crossref","first-page":"e11408","DOI":"10.1371\/journal.pone.0011408","article-title":"Copy number analysis identifies novel interactions between genomic loci in ovarian cancer","volume":"5","author":"Gorringe","year":"2010","journal-title":"PLoS ONE"},{"key":"2022061704592231200_bib7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2022061704592231200_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4161\/cc.11.1.18775","article-title":"An integrated view of cyclin E function and regulation","volume":"11","author":"Siu","year":"2012","journal-title":"Cell Cycle"},{"key":"2022061704592231200_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/45836","article-title":"Deregulated cyclin E induces chromosome instability","volume":"401","author":"Spruck","year":"1999","journal-title":"Nature"},{"key":"2022061704592231200_bib10","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0960-9822(02)01225-3","article-title":"p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation","volume":"12","author":"Minella","year":"2002","journal-title":"Curr Biol"},{"key":"2022061704592231200_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccr.2005.06.010","article-title":"A mouse model for cyclin E-dependent genetic instability and tumorigenesis","volume":"8","author":"Loeb","year":"2005","journal-title":"Cancer Cell"},{"key":"2022061704592231200_bib12","doi-asserted-by":"crossref","first-page":"e30996","DOI":"10.1371\/journal.pone.0030996","article-title":"Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome","volume":"7","author":"Engler","year":"2012","journal-title":"PLoS ONE"},{"key":"2022061704592231200_bib13","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","article-title":"Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas","volume":"15","author":"Etemadmoghadam","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061704592231200_bib14","doi-asserted-by":"crossref","first-page":"e15498","DOI":"10.1371\/journal.pone.0015498","article-title":"Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer","volume":"5","author":"Etemadmoghadam","year":"2010","journal-title":"PLoS ONE"},{"key":"2022061704592231200_bib15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ygyno.2009.08.023","article-title":"Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma","volume":"115","author":"Liu","year":"2009","journal-title":"Gynecol Oncol"},{"key":"2022061704592231200_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/PAP.0b013e3181ecdee1","article-title":"A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube","volume":"17","author":"Mehrad","year":"2010","journal-title":"Adv Anat Pathol"},{"key":"2022061704592231200_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/pgp.0b013e31814b191f","article-title":"Serous carcinogenesis in the fallopian tube: a descriptive classification","volume":"27","author":"Jarboe","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"2022061704592231200_bib18","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/nprot.2012.097","article-title":"Primary culture and immortalization of human fallopian tube secretory epithelial cells","volume":"7","author":"Karst","year":"2012","journal-title":"Nat Protoc"},{"key":"2022061704592231200_bib19","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1073\/pnas.1017300108","article-title":"Modeling high-grade serous ovarian carcinogenesis from the fallopian tube","volume":"108","author":"Karst","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061704592231200_bib20","doi-asserted-by":"crossref","first-page":"14723","DOI":"10.1073\/pnas.95.25.14723","article-title":"Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization","volume":"95","author":"Counter","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061704592231200_bib21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1593\/neo.08120","article-title":"Different mutant\/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells","volume":"10","author":"Junk","year":"2008","journal-title":"Neoplasia"},{"key":"2022061704592231200_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2022061704592231200_bib23","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2022061704592231200_bib24","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/cncr.24987","article-title":"Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer","volume":"116","author":"Nakayama","year":"2010","journal-title":"Cancer"},{"key":"2022061704592231200_bib25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1541-7786.MCR-10-0344","article-title":"MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E","volume":"9","author":"Ofir","year":"2011","journal-title":"Mol Cancer Res"},{"key":"2022061704592231200_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1128\/MCB.17.1.453","article-title":"Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E","volume":"17","author":"Bortner","year":"1997","journal-title":"Mol Cell Biol"},{"key":"2022061704592231200_bib27","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1073\/pnas.0606537104","article-title":"Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas","volume":"104","author":"Ma","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061704592231200_bib28","doi-asserted-by":"crossref","first-page":"7245","DOI":"10.1038\/sj.onc.1209713","article-title":"Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland","volume":"25","author":"Smith","year":"2006","journal-title":"Oncogene"},{"key":"2022061704592231200_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol"},{"key":"2022061704592231200_bib30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/gyno.2000.6071","article-title":"Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis","volume":"80","author":"Paley","year":"2001","journal-title":"Gynecol Oncol"},{"key":"2022061704592231200_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"2022061704592231200_bib32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"2022061704592231200_bib33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nature05268","article-title":"Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints","volume":"444","author":"Bartkova","year":"2006","journal-title":"Nature"},{"key":"2022061704592231200_bib34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc2693","article-title":"When mutants gain new powers: news from the mutant p53 field","volume":"9","author":"Brosh","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2022061704592231200_bib35","doi-asserted-by":"crossref","first-page":"8746","DOI":"10.1074\/jbc.274.13.8746","article-title":"Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity","volume":"274","author":"Brown","year":"1999","journal-title":"J Biol Chem"},{"key":"2022061704592231200_bib36","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","article-title":"Nucleotide deficiency promotes genomic instability in early stages of cancer development","volume":"145","author":"Bester","year":"2011","journal-title":"Cell"},{"key":"2022061704592231200_bib37","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1038\/onc.2012.387","article-title":"Increased replication initiation and conflicts with transcription underlie cyclin E-induced replication stress","volume":"32","author":"Jones","year":"2013","journal-title":"Oncogene"},{"key":"2022061704592231200_bib38","doi-asserted-by":"crossref","first-page":"pii: 920161","DOI":"10.4061\/2010\/920161","article-title":"H2AX phosphorylation: its role in DNA damage response and cancer therapy","author":"Podhorecka","year":"2010","journal-title":"J Nucleic Acids"},{"key":"2022061704592231200_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nprot.2006.5","article-title":"The comet assay: a method to measure DNA damage in individual cells","volume":"1","author":"Olive","year":"2006","journal-title":"Nat Protoc"},{"key":"2022061704592231200_bib40","doi-asserted-by":"crossref","first-page":"932371","DOI":"10.1155\/2010\/932371","article-title":"Ovarian cancer pathogenesis: a model in evolution","volume":"2010","author":"Karst","year":"2010","journal-title":"J Oncol"},{"key":"2022061704592231200_bib41","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/modpathol.2010.60","article-title":"Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase","volume":"23","author":"Sehdev","year":"2010","journal-title":"Mod Pathol"},{"key":"2022061704592231200_bib42","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1038\/sj.onc.1210518","article-title":"p53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability","volume":"26","author":"Minella","year":"2007","journal-title":"Oncogene"},{"key":"2022061704592231200_bib43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/path.2217","article-title":"DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification","volume":"213","author":"Nowee","year":"2007","journal-title":"J Pathol"},{"key":"2022061704592231200_bib44","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1038\/sj.onc.1206621","article-title":"Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma","volume":"22","author":"Snijders","year":"2003","journal-title":"Oncogene"},{"key":"2022061704592231200_bib45","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-09-4094","article-title":"Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification","volume":"70","author":"Bagheri-Yarmand","year":"2010","journal-title":"Cancer Res"},{"key":"2022061704592231200_bib46","doi-asserted-by":"crossref","first-page":"e1002538","DOI":"10.1371\/journal.pgen.1002538","article-title":"LMW-E\/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1\/2-mTOR pathway in breast cancer patients","volume":"8","author":"Duong","year":"2012","journal-title":"PLoS Genet"},{"key":"2022061704592231200_bib47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/path.4147","article-title":"Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development","volume":"229","author":"Sheu","year":"2013","journal-title":"J Pathol"},{"key":"2022061704592231200_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccr.2012.05.015","article-title":"A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1\/2","volume":"22","author":"Schlacher","year":"2012","journal-title":"Cancer Cell"},{"key":"2022061704592231200_bib49","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1093\/nar\/gkt348","article-title":"FANCD2 regulates BLM complex functions independently of FANCI to promote replication fork recovery","volume":"41","author":"Chaudhury","year":"2013","journal-title":"Nucleic Acids Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/74\/4\/1141\/2714807\/1141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/74\/4\/1141\/2714807\/1141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:59:12Z","timestamp":1746075552000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/74\/4\/1141\/599292\/Cyclin-E1-Deregulation-Occurs-Early-in-Secretory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,15]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,2,16]]},"published-print":{"date-parts":[[2014,2,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-13-2247","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22402532","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6506081.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22402541","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22402541.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6506081","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22402538","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22402544.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22402532.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22402544","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22402538.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,15]]}}}